SM
CTIC

Sabby Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Sabby Management’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-57,567
Closed -$708K – 405
2015
Q4 		$708K Buy
+57,567
New +$769K 0.04% 214
2015
Q2 		– Sell
-33,163
Closed -$640K – 399
2015
Q1 		$600K Buy
33,163
+8,663
+35% +$195K 0.03% 224
2014
Q4 		$578K Buy
+24,500
New +$566K 0.02% 180

Other funds holding CTIC

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sabby Management's CTIC Position: Q1 2016 in Review

Sabby Management sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q1 2016, closing a stake of 57,567 shares — an estimated $708K sold.

Sabby Management first reported a position in CTIC in Q4 2014 and held it in 3 quarters. The position peaked at $708K in Q4 2015. 80 funds tracked by Wall St. Rank hold CTIC as of Q1 2016.

  • Sabby Management reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q1 2016 after selling out during the quarter.
  • Sabby Management sold 57,567 CTI BioPharma Corp. (DE) Common Stock shares in Q1 2016, an estimated $708K.
  • Sabby Management first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 3 quarters.
  • Sabby Management's CTI BioPharma Corp. (DE) Common Stock position peaked at $708K in Q4 2015.
  • 80 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q1 2016.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.